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A B S T R A C T
Aims: Depression in diabetes mellitus (DM) is common and is associated with poor health outcomes.
Peer support DM interventions include encouraging interactions that could improve depressive symp-
toms.We examined intervention effects for those with and without depressive symptoms in a peer support
trial.
Methods: The 1-year ENCOURAGE trial included 424 persons with DM living in rural Alabama. Inter-
vention participants worked with community volunteers who encouraged participants to engage in daily
self-management; control arm participants received usual care. Outcomes included HbA1c, body mass
index (BMI) and quality of life (QoL) with EuroQuol-5D (range 0.0–1.0). Depressive symptoms were as-
sessed with the Patient Health Questionnaire (PHQ-8, range 0–24). Generalized Additive Models (GAM)
examined control–intervention differences in changes in HbA1c, BMI, and QoL for those with PHQ-8 ≥ 5
and PHQ-8 < 5.
Results: Of the 424 participants enrolled at baseline, 355 completed follow-up and had data were that
could be included into the study; they were aged 60.2 ± 12.1 years, 87% African American, 75% female,
and 39% insulin-treated. In an overall GAM adjusting for imbalance across trial arms and time-related
covariates, depressive symptoms improved for all, but after 15 months of follow-up intervention, par-
ticipants experienced greater reduction in PHQ-8 score than control participants (p = 0.01). In stratiﬁed
analyses, those with PHQ-8 ≥ 5 had unchanged HbA1c, lost weight (p = 0.03) and improved QoL (p = 0.04).
Those with PHQ-8 < 5 also had unchanged HbA1c and lost weight, but did not improve QoL (p = 0.06).
Conclusions: Peer support improved depressive symptoms for all, but resulted in greater weight loss and
gains in QoL for those with baseline depressive symptoms compared to those without.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Both diabetes and depression are among the most prevalent
medical conditions affecting Americans, and they commonly co-
occur in the same patient. The prevalence estimates for depression
among adults with diabetes range from 5.0 to 34.4% [1]. Several
mechanismsmay underlie the diabetes–depression association. Both
receiving the diagnosis of diabetes and the complexity of diabetes
self-management can lead to depressive symptoms [1]. Addition-
ally, at the metabolic level, relationships between diabetes and
depression may be mediated by increased cortisol, hyperactivity of
the hypothalamus–pituitary–adrenal axis, and activation of pro-
inﬂammatory cytokines in the central nervous system [2–4].
Untreated depression in diabetic individuals is associated with
poor glycemic control [5,6]; increased risk of complications [7],
including diabetic polyneuropathy, microvascular angiopathy and
diabetic foot ulcers [8]; increased health expenditures [9]; risk of
cardiovascular disease [10] and excess mortality [11]. Thus, in a
2014 position statement, the American Diabetes Association placed
special emphasis on recognizing and managing subclinical and clin-
ical depression among patients with diabetes, and included
recommendations on screening and treatment of depression into
the current diabetes clinical practice guidelines [12].
Although the need for interventions that simultaneously target
depression and diabetes has been articulated, there is mixed evi-
dence regarding the effectiveness of available interventions. Recent
systematic reviews found that psychological interventions focused
on depressive symptoms in individuals with diabetes may have
reduced depressive symptoms, but did not improve glycemic control
[13,14]. Based on data from nineteen randomized clinical trials (RCT),
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a Cochrane review concluded that there was low evidence of im-
proved glycemic control in psychological intervention trials, including
both individual and group cognitive-behavioral, interpersonal, or
supportive psychotherapy of depressive symptoms among indi-
viduals with diabetes [15]. The Cochrane review alsomentioned that
among depressed individuals with diabetes health-related quality
of life did not signiﬁcantly improve in the 3 trials included in the
review, andmedication adherence was investigated only in one trial
[15].
A potential approach to addressing the challenge of depression
and diabetes may lie in peer support. Peer support or peer coach-
ing interventions increasingly show promise for improving health
outcomes among diabetic patients, especially in settings with limited
medical resources or a low level of organized self-management
support [16–19]. Previous research has demonstrated that com-
pared to usual care peer coaching improves glycemic control [18],
increases protective high density lipoprotein (HDL) cholesterol [19],
reduces body mass index [19] and reduces hospitalizations among
patients with diabetes [20]. However little evidence exists regard-
ingwhether peer coaching can decrease depressive symptoms among
adults with diabetes or speciﬁcally improve health outcomes in di-
abetes associated with depression. Therefore, we examined the
effects of a peer support intervention among mostly African Amer-
ican participants, with and without depressive symptoms from a
community-based trial in rural southern Alabama. We hypoth-
esized that, compared with usual care, the peer support intervention
would decrease depressive symptoms andwould have greater effects
among participants with depressive symptoms than among those
without depressive symptoms, namely greater improvements in
glycosylated hemoglobin A1c (HbA1c), body mass index (BMI) and
health related quality of life (QoL).
Methods
Setting and participants
This study utilized data from the 1-year cluster-randomized
community-based ENCOURAGE pragmatic trial, conducted in 2010–
2012 in rural Alabama counties that are part of a region known as
the Black Belt (Fig. 1). This region is characterized by a high burden
of chronic diseases like diabetes and limited medical resources.
Details of participant recruitment, study design, and themain results
are described elsewhere [21–23]. Brieﬂy, 424 participants with di-
abetes were recruited in 8 partnering communities via respondent
driven sampling [21]. Participants were eligible if they had been told
by a doctor or nurse that they had diabetes and if they were willing
to work with a peer coach to help with diabetes self-management.
Exclusions were the absence of a regular primary care provider, ad-
vancedmedical illness that limited life expectancy, and unwillingness
to work with a peer coach. Peer coaches were recruited from the
same communities and had to be diabetic themselves or to have
personal experience caring for someone with diabetes. All partici-
pants provided written informed consent, and the University of
Alabama at Birmingham Institutional Review Board approved the
study protocol. The trial is registered at Clinicaltrials.gov; registra-
tion number NCT02460718.
Peer support intervention
Peer coaches were identiﬁed by community coordinators/
community partners, and those, who completed training and were
certiﬁed became study interventionists. Peer coaches were com-
pensated for a total of $790 for their effort. Prior to the start of the
intervention, peer coaches received 12 hours of training over 2 days
covering the basics of diabetes, diabetes self-management, moti-
vational interviewing, research ethics, and the study protocol. Peer
coaches were also trained to help participants develop and achieve
realistic diabetes management goals, provide social and emotion-
al support, and maximize the utility of visits to the doctor. Peers
who completed the training successfully were paired with 2–14
(mean 6–7) intervention participants [22].
Each coach–participant pair had a 45–60 minute initial phone
or in-person meeting followed by weekly phone meetings over next
2 months and then monthly meetings over the last 8 months. Peer
coaches were allowed to make more contacts with participants if
needed. Contacts were focused on selecting individualized self-
management goals and providing coaching on how to achieve the
goals. Some contacts were scheduled prior to regular visits to the
diabetes care provider and focused on planning for the physician
encounter. The median duration of the peer coach–participant en-
counter was 9min with maximum up to 47 minutes. Contacts were
highly individualized and mostly unstructured.
Usual care
Both intervention- and control-arm participants received a one
hour group diabetes education class at enrollment covering basics
of diabetes and its self-management emphasizing healthy eating and
physical activity; stress reduction; and visits to the doctor [22]. All
participants were presented with a personalized diabetes card in-
Figure 1. Alabama counties included into ENCOURAGE trial. Displays the map of
the State of Alabama. Recruitment of the participants for the ENCOURAGE trial took
place in the counties, highlighted in orange. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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cluding their baseline HbA1c and body weight, followed by a
5-minute counseling session explaining the results.
Study design
The study was a cluster RCT with the initial plan calling for ran-
domization of medical practices to either the intervention or control
arm. However, participant recruitment at the practices lagged and
was expanded to surrounding communities [21]. Thus, since there
was one practice enrolled per community, the cluster or unit of ran-
domization became the community. Clusters were randomly assigned
to a trial arm by a random number generator. Since the interven-
tion acted at the individual level, analyses were conducted at the
individual level, and peer coaches and participants were not blinded
to the arm assignment [22].
Depressive symptoms
Depressive symptoms were measured at baseline and follow-
up using the 8-item Personal Health Questionnaire (PHQ-8), which
has been validated for use in this population [24]. The PHQ-8 results
in a single summary score ranging from 0 to 24; a PHQ-8 score ≥ 5
represents mild or greater depressive symptoms, and a PHQ-8 score
≥10 represents moderate or greater depressive symptoms [24].
Outcomes
Changes in HbA1c, BMI, and QoL from baseline to follow-up were
contrasted between intervention and control arms separately among
participants with and without depressive symptoms. Baseline and
follow-up data were collected by trained and certiﬁed study per-
sonnel following a standardized protocol in community venues:
churches, schools, libraries, community centers and very small
number were collected at participants’ home. HbA1c was mea-
sured using point-of-service equipment and capillary ﬁnger stick
blood (National Glycohemoglobin Standardization Project compli-
ant DCA2000), and BMIwas calculated asweight in kilograms divided
by the square of height in meters. Health-related QoL was as-
sessed using the Euroqol EQ-5D, a widely validated instrument
applicable to a wide range of health conditions and treatments and
measuring self-reported levels of mobility, self-care, usual daily ac-
tivities, pain/discomfort and anxiety/depression [25].
Statistical analysis
We used student t-tests and chi-square tests to compare inter-
vention participants and controls on baseline characteristics,
separately among those reporting mild or greater depressive symp-
toms (PHQ-8 ≥ 5) and those reporting no depressive symptoms (PHQ-
8 < 5). Baseline characteristics included age, race, education, income,
duration of diabetes in years, use of insulin, and season of data col-
lection (since HbA1c values vary by season) [26].
The follow-up time for this study was extended from the ini-
tially planned 12–15 months to maximize follow-up data collection
and to accommodate community members who wanted to provide
follow-up data, concordant with the community-engaged re-
search framework [22,23]. The length of trial extension after 15
months was up to 177 days. The prolonged follow-up improved
generalizability, an important objective of pragmatic trials, but ne-
cessitated the use of non-traditional approaches to analyze the trial’s
results. Speciﬁcally, generalized additive mixed models (GAMMs)
were employed, which also revealedmarkedly non-linear effects over
time [23]. GAMMs were constructed to assess the difference in
changes in PHQ-8 score over time between the intervention and
control arms, as well as differences in the study outcomes strati-
ﬁed on PHQ-8 scores (<5 and ≥5). All models were adjusted for
clustering, season of data collection, calendar time between base-
line and follow-up, baseline PHQ-8 score, and imbalance in
participant characteristics across trial arms, speciﬁcally race, age,
income, and education. All analyses were intention-to-treat. SAS
version 9.4 and R statistical programing language version 3.01.1 were
utilized to conduct the analyses.
Role of the funding source
Funding for this research was provided by the American Academy
of Family Physicians Foundation through the Peers for Progress
program with support from the Eli Lilly and Company Foundation.
Representatives of the funding agency have not been involved in
the collection, management, analysis, or interpretation of the data.
Results
Of the 424 enrolled trial participants, 360 were available at
follow-up. Five participants had missing PHQ-8 scores at baseline;
therefore, the analytic sample was comprised of 355 individuals.
At baseline, 50% (n = 177) had PHQ-8 scores ≥5 and 25% (n = 90)
had PHQ-8 scores ≥10. The mean age of trial participants was 60
years, 87% (n = 313) were African Americans, and 75% (n = 271)
were women.
Table 1presents participants’ baseline characteristics con-
trasted between trial arms among those with PHQ-8 scores ≥5 and
<5. Among those with PHQ-8 ≥ 5, intervention and control partici-
pants were similar at baseline except that the intervention group
included more African Americans (95.5% vs. 84.3%, respectively).
Among those with PHQ-8 < 5, intervention-arm participants were
signiﬁcantly more likely to be African American (93.7%, vs. 77.6%
among controls), and to be younger (mean age 59.5 vs. 63.2 years
among controls). Among those with PHQ-8 < 5 control partici-
pants had slightly higher mean PHQ-8 score than the intervention
group (p = 0.08). The season of data collection differed in both those
with and without depressive symptoms.
Fig. 2a presents plots from the GAMMmodel, displaying control–
intervention differences in PHQ-8 score changes from baseline to
follow-up in the overall sample. The higher panel presents the raw
change in PHQ-8 scores for intervention and control arm partici-
pants. The lower panel depicts the adjusted change in PHQ-8 score
attributable to the intervention. Changes in PHQ-8 scores differed
signiﬁcantly between the control and intervention group over time
(p = 0.03). As can be seen from the high estimated degrees of freedom
(EDF = 8), the intervention effects varied over time in a non-linear
fashion. Early in follow-up, between 12 and 15 months, control par-
ticipants had a greater improvement than intervention participants,
whereas, to the contrary, after about 15 months, intervention par-
ticipants had a greater improvement in depressive symptoms.
Fig. 2b presents control–intervention differences in changes in
PHQ-8 scores for those with PHQ-8 < 5 and ≥5. Among partici-
pants with baseline PHQ-8 < 5, there were no statistically signiﬁcant
control–intervention differences in changes in PHQ-8 scores
(p = 0.29). In contrast, among participants with PHQ-8 ≥ 5 at base-
line, there was a statistically signiﬁcant trend in the control–
intervention difference in change in PHQ-8 scores over time
(p = 0.04). As can be seen in the upper panel, both intervention and
control participants improved their scores, but early in follow-up,
improvements were greater in the control group.
Fig. 3a, 3b and 3c present control–intervention differences in the
changes in HbA1c, BMI, and QoL over time, stratiﬁed on PHQ-8 < 5
and ≥5 at baseline. For both thosewith andwithout depressive symp-
toms, there was no statistically signiﬁcant effect of the intervention
on change in HbA1c, after adjustment (Fig. 3a). Fig. 3b presents
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changes in BMI attributable to the intervention, with nonlinear effects
for both those with and without depressive symptoms. For those
without depressive symptoms, the intervention resulted in greater
weight loss early and late during follow-up with less weight loss
from 13 to 18 months (p = 0.05, EDF = 4). For those with depres-
sive symptoms at baseline, intervention participants followed after
15 months experienced greater weight loss than control partici-
pants (p = 0.02, EDF = 3). Fig. 3c presents changes in QoL attributable
to the intervention, with highly nonlinear effects. For those without
depressive symptoms at baseline, there were borderline interven-
tion effects (p = 0.06, EDF = 7). For those with depressive symptoms
at baseline, there were statistically signiﬁcant intervention effects
with modestly lower gains in QoL at 15 months and greater gains
in Qol after 17–18 months of follow-up among intervention par-
ticipants compared to the control participants. (p = 0.04, EDF = 8).
Discussion
This study presents data from a pragmatic cluster-randomized
effectiveness ENCOURAGE trial of the peer coaching intervention,
conducted among diabetic, mostly African American participants
in rural Alabama with limited access to medical resources. As pre-
viously reported, the peer-coaching interventionmay have promoted
weight loss, reduction in systolic blood pressure, and improved
quality of life compared to the control in participants who were fol-
lowed after 15 months [22]. In addition to the trial’s main results,
summarized by Safford et al., the present study assessed the inter-
vention effects separately among subgroups of participants with or
without elevated depressive symptoms at baseline. Overall after
initial worsening the peer-coaching intervention improved depres-
sive symptoms at/after 15 months of follow-up. Our examination
of the intervention effects on participants with and without de-
pressive symptoms revealed no effects on glycemic control, but more
signiﬁcant intervention effects on weight loss and improvements
in quality of life for those with baseline depressive symptoms than
for those without depressive symptoms, especially seen in the later
follow-up period.
Our study supports the previous research ﬁndings showing that
peer coaching might be an especially effective intervention for the
situation when diabetes is complicated with poor mental health.
The RCT conducted by Chan et al. among 628 Hong Kong patients
with type 2 diabetes has demonstrated that peer coaching inter-
vention has reduced overnight hospitalizations, day admissions and
improved medication adherence only among patients with el-
evated baseline diabetic distress [20]. These intervention effects were
not seen among those with no diabetic distress at baseline [20]. In
another study of patients with diabetes and comorbid emotional
disorders, peer education intervention reduced anxiety, depres-
sion and distress and improved self-management skills and quality
of life [27].
Several mechanisms can explain why peer coachingmay bemore
effective for individuals with diabetes and with depressive symp-
toms than among non-depressed. Peer support interventions may
reduce symptoms of depression through encouraging, supportive
interactions that minimize isolation and buffer stress by sharing
health and self-management information, and providing positive
role modeling [28,29]. By its nature peer support entails group or
one-on-one communication between non-professionals with similar
stressors or health problems, and can be delivered in person or over
the telephone or the Internet [29]. Enhanced social support via fre-
quent contact with a peer may be a mediator of the greater beneﬁts
of the intervention that we observed among participants with both
depressive symptoms and diabetes.
The study’s strengths include an ability to build a network of
trained peer coaches and deliver highly personable and individu-
alized intervention to the group of participants with diabetes who
are very hard to reach by traditional medical services. This analy-
sis used GAMMs to accommodate the prolonged follow-up
experienced in this study, resulting in retention of 85% of the study’s
mostly minority participants. This analytic method allowed poten-
tial differential intervention effects over time to emerge, and
suggested that intervention effects may be greatest after 15 months,
a possibility supported by the fact that peer coaches and partici-
pants often continued their relationships well beyond the conclusion
of the study. Different times between baseline and follow-up data
collection (shorter for some participants vs. longer for others) did
not explain the observed differences between the trial arm, as shown
in the report of the trial’s main results [22]. However, the use of
Table 1
Baseline characteristics of ENCOURAGE participants by depressive symptoms at baseline
Overall Depressed (PHQ-8 ≥ 5) Not depressed (PHQ-8 < 5)









n, (%) n, (%) n, (%) n, (%) n, (%)
African American 313(87.4) 84(95.5) 75(84.3) 0.01 74(93.7) 76(77.6) 0.003
Female 271(75.3) 69(78.4) 66(74.2) 0.51 62(77.5) 71(72.5) 0.44
<High school education 111(31.2) 32(37.2) 29(32.6) 0.52 21(26.3) 27(27.8) 0.81
Annual household income < $40,000 289(90.3) 74(94.9) 77(92.8) 0.58 64(91.4) 74(82.2) 0.09
Insulin therapy 142(39.6) 39(44.2) 43(48.3) 0.59 28(35.0) 29(29.6) 0.44
Season of baseline data collection <.0001 <.0001
Spring 92(25.9) 36(40.9) 11(12.4) 35(43.8) 10(10.2)
Summer 235(66.2) 52(59.1) 67(75.3) 45(56.3) 71(72.5)
Winter 28(7.9) 0 11(12.4) 0 17(17.4)
Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ± SD
Age, years 60.2 ± 12.1 59.0 ± 11.3 58.8 ± 11.7 0.91 59.5 ± 12.4 63.2 ± 12.4 0.046
HbA1c, % 7.9 ± 2.0 8.0 ± 2.0 8.1 ± 1.9 0.76 8.0 ± 2.1 7.7 ± 1.8 0.24
Time with diabetes, years 13.3 ± 11.9 12.9 ± 11.6 12.5 ± 10.6 0.84 12.9 ± 11.4 13.8 ± 13 0.63
Diabetes distress score 2.1 ± 1.2 2.6 ± 1.4 2.7 ± 1.2 0.44 1.6 ± 0.8 1.6 ± 0.8 0.88
PHQ-8 score 6.4 ± 5.6 10.6 ± 4.6 10.9 ± 5.0 0.64 1.8 ± 1.4 2.2 ± 1.5 0.08
Body mass index, kg/m2 36.3 ± 8.5 36.6 ± 6.8 37.2 ± 9.8 0.85 36.4 ± 8.6 35.0 ± 8.3 0.27
Systolic blood pressure, mmHg 135.2 ± 21.4 136.9 ± 22.4 133.6 ± 21.1 0.32 132.1 ± 20.8 137.6 ± 21 0.08
Diastolic blood pressure, mmHg 83.0 ± 12.9 85.0 ± 12.0 83.0 ± 12.6 0.27 82.2 ± 11.8 81.7 ± 14.7 0.81
EuroQuol index 0.8 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.05 0.8 ± 0.1 0.8 ± 0.1 0.82
Bold indicates p < .05.
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Figure 2. (a) Overall change in depressive symptoms over time. Control (C)–intervention (I) arm differences in change in depressive symptoms (measured by PHQ-8) for all
study participants, showing raw change scores and change scores from generalized additive models adjusting for differences in time from baseline to follow-up, season,
baseline value, clustering, education, and race. The top graph presents the raw change scores for each participant, with circles and solid lines signifying control arm and
triangles and dotted lines signifying intervention arm. The x axis shows the time in days between baseline and follow-up. Vertical lines show the 12- and 15-month follow-
up points. The bottom graph presents the differences between intervention and control change scores from generalized additive models with p-values from tests of statistical
signiﬁcance of the difference between control and intervention arms. EDF = estimated degrees of freedom; GAM = generalized additive mixed models. (b) Change in de-
pressive symptoms over time, stratiﬁed by baseline PHQ-8 score. Control (C)–intervention (I) arm differences in change in depressive symptoms (measured by PHQ-8) for
participants with baseline PhQ-8 < 5 (left panel) and with PHQ-8 ≥ 5 (right panel), showing raw change scores (top of each panel) and change scores from generalized ad-
ditive models adjusting for differences in time from baseline to follow-up, season, baseline value, clustering, education, and race. The top graph presents the raw change
scores for each participant, with circles and solid lines signifying control arm and triangles and dotted lines signifying intervention arm. The x axis shows the time in days
between baseline and follow-up. Vertical lines show the 12 and 15-month follow-up points. The bottom graph in each panel presents the differences between intervention
and control change scores from generalized additive models with p-values from tests of statistical signiﬁcance of the difference between control and intervention arms.
EDF = estimated degrees of freedom; GAM = generalized additive mixed models.
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GAMMs to analyze the data has several disadvantages. First, there
is an inability to conclude whether he intervention effects were sig-
niﬁcant at any given time, and second, there is the unfamiliarity of
this method in reporting trial results. Additional limitations worth
noting include the single geographic region, which may limit
generalizability. Because the intervention was delivered in the com-
munity, we could not account for differences in peer-coaching style
or use of skills acquired during training.
In conclusion, this peer coaching intervention may have had
differential effects for participants with and without depressive
symptoms. Participants with mild or greater depressive symp-
toms at baseline may have experienced greater weight loss and
gains in quality of life compared to those without depressive
symptoms after receiving peer coaching intervention. The inter-
vention did not result in improved glycemic control regardless of
the presence or absence of depressive symptoms. Peer support
intervention may also have a delayed effect representing the
possibility that some behavioral changes require time to occur.
Peer support holds promise for the treatment of comorbid diabe-
tes mellitus and depressive symptoms, especially in settings with
few medical resources.
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Figure 3. (a) Change in HbA1c over time, stratiﬁed by baseline PHQ-8 score. (b) Change in BMI over time, stratiﬁed by baseline PHQ-8 score. (c) Change in QoL over time,
stratiﬁed by baseline PHQ-8 score. Control (C)–intervention (I) arm differences in change in hemoglobin HBA1C (HbA1c – Fig. 3a), body mass index (BMI – Fig. 3b) and
quality of life (QoL – Fig. 3c), separately, for participants with baseline PhQ-8 < 5 (left panel) and with PHQ-8 ≥ 5 (right panel) on each graph, showing raw change scores
(top of each panel) and change scores from generalized additive models adjusting for differences in time from baseline to follow-up, season, baseline value, clustering, ed-
ucation, and race. The top graph presents the raw change scores for each participant, with circles and solid lines signifying control arm and triangles and dotted lines signifying
intervention arm. The x axis shows the time in days between baseline and follow-up. Vertical lines show the 12- and 15-month follow-up points. The bottom graph in each
panel presents the differences between intervention and control change scores from generalized additive models with p-values from tests of statistical signiﬁcance of the
difference between control and intervention arms. EDF = estimated degrees of freedom; GAM = generalized additive mixed models.
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